AR and prostate carcinoma: Recent studies by Welti et al. demonstrate that CCS1477, an orally bioavailable and selective inhibitor of the p300/CBP, potently blocks both AR-FL and AR-V7 signaling and exhibits prominent antitumor activity in cell and animal models of human prostate cancer [78].